Triple-Combination Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Moderate-to-Severe Acne: Efficacy and Safety Results From a Pooled Phase 3 Analysis

Main Article Content

Linda Stein Gold
Michael Gold
Leon Kircik
Julie Harper
James Del Rosso
Christopher Bunick
Neal Bhatia
Hilary Baldwin
Zoe Draelos
Valerie Callender
Edward Lain


acne, combination treatment, triple-combination, topical, clindamycin phosphate, benzoyl peroxide, adapalene


Background: A three-pronged approach to acne treatment that combines an antibiotic, antimicrobial agent, and retinoid in a single formulation may be more efficacious than single/double treatments while potentially reducing antibiotic resistance. IDP-126 polymeric mesh gel (clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide [BPO] 3.1%)—the first fixed-dose triple-combination acne topical in development—demonstrated superior efficacy to vehicle and component dyads, with good safety/tolerability in a phase 2 and two phase 3 studies of moderate-to-severe acne. This post hoc analysis further examined efficacy and safety of IDP-126 in data pooled from these phase 3 studies.

Methods: In two identical phase 3 (N=183; N=180; NCT04214639; NCT04214652), double-blind, randomized, 12-week studies, participants aged ≥9 years with moderate-to-severe acne were randomized 2:1 to receive once-daily IDP-126 or vehicle gel. Endpoints included ≥2-grade reduction from baseline in Evaluator’s Global Severity Score and clear/almost clear skin (treatment success) and least-squares mean percent change from baseline in inflammatory/noninflammatory lesion counts. Treatment-emergent adverse events (TEAEs) and cutaneous safety/tolerability were evaluated.

Results: A total of 363 participants were randomized; a majority were female (58.4%) and had moderate acne (91.2%). At week 12, 50.0% of participants achieved treatment success with IDP-126 versus 22.6% with vehicle gel (P<0.001). IDP-126 resulted in over 70% reductions in inflammatory and noninflammatory lesions at week 12, which were significantly greater than vehicle (inflammatory: 77.9% vs 57.9%, respectively; noninflammatory: 73.0% vs 48.2%; P<0.001, both). Most TEAEs were of mild-moderate severity, and <3% of IDP-126-treated participants discontinued study/treatment due to AEs. Transient increases from baseline in investigator-assessed scaling and erythema and participant-assessed itching, burning, and stinging were observed with IDP-126, but resolved back to or near baseline values by week 12.

Conclusions: The innovative fixed-dose triple-combination clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% gel was efficacious and well tolerated in children, adolescents, and adults with moderate-to-severe acne. Half of participants achieved clear or almost clear skin by 12 weeks, rates not previously seen in clinical studies of other topical acne products.

Funding: Ortho Dermatologics


1. Stein Gold L, et al. Am J Clin Dermatol. 2021; 23(1):93-104.

2. Stein Gold L, et al. J Am Acad Dermatol. 2023; DOI:

3. Martin AR, et al. Clin Exp Dermatol. 2001;26(5):380-385.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>